
Bausch Health has run into problems with the US authorities, as the Canadian company is being investigated for having marketed three plaque psoriasis treatments and one fungal treatment for unintended use, media Endpoints News reports based on a Stat News story.
According to documents seen by Stat News, Bausch is intending to comply with the probe by the US Department of Justice (DOJ), although the uses of the drugs that the investigation concerns are not specified. Bausch Health leadership has therefore instructed employees to preserve all documents and communications, a move known as a ”legal hold.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app